Articles By Rob Wright, Chief Editor
When It’s Time8/2/2021
When pondering if she wanted to spend the next 10 to 15 years continuing to climb that academic ladder or do something that would be impactful for patients, Laura Niklason, M.D., Ph.D., opted for the latter.
IPO, M&A, And SPAC — 3 Life Science Execs Recount Going Public8/2/2021
Taking a company public may not be every entrepreneur’s dream, but it is for many life sciences companies. As 2020 forever changed how IPOs are done, it seems like there is a great opportunity to capture some wisdom from those who have been there, done that.
Mental Wellness — The Next Big Thing7/30/2021
Recent events of female athletes expressing the need to focus on their mental health seems to point toward mental wellness being one of the next big things, along with women leaders being willing to "rewrite the rules."
How A First-Time CEO Transformed Retrophin Into Travere Therapeutics7/1/2021
Eric Dube, Ph.D., was dubious when an executive recruiter pitched him the CEO position at previously embattled Retrophin (remember Martin Shkreli?). But he took the job in January 2019 and now has guided the $1.5 billion biopharma as it has increased sales, implemented a new diverse and inclusive culture, advanced its pipeline, and adopted a new name (Travere).
Is Government-Enabled IP Theft Ever A Good Thing?7/1/2021
I believe waiving IP protections on COVID-19 vaccines (developed by three U.S. companies in record time) will not have any appreciable impact on fixing the global health crisis in the short term.
Building A COVID-19 Vaccine Company In A Few Months6/1/2021
Mei Mei Hu, J.D., and her husband Lou Reese know what it’s like to develop a drug during a pandemic. Nearly 20 years ago they helped develop a vaccine and antibody test for the SARS outbreak. But now they were considering starting a COVID-19 vaccine company — during 2020.
Be The Inspiration6/1/2021
The world is hurting. Now more than ever, people need and want to be inspired by people. Just imagine what we can accomplish if we all strive to be the inspiration we seek.
From Aha Moment To $10 Billion Biopharma5/3/2021
In 2012 Neil Kumar, Ph.D. read an article in Nature Biotechnology and was so inspired by the paper’s theories on drug discovery and development, that he eventually decided to quit his job and start his own biopharma called BridgeBio.
Got Your Zoom On?5/3/2021
The majority of my interviews have been over the phone. As for how many interviews for feature articles I’ve conducted via Zoom, the number is exactly two — both appearing in this issue.